Posted by Michael Wonder on 24 Feb 2021
Takeda’s drug for acute hereditary angioedema seizure to get larger benefits
24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for its acute hereditary angioedema seizure treatment, Firazyr, from next month.
The ministry will expand the insurance benefits for Firazyr to two doses per patient from the existing one-dose regimen. The expanded insurance benefit will allow patients with confirmed hereditary angioedema due to a deficiency of a C1-esterase inhibitor to receive reimbursement for up to two doses.
